AstraZeneca to share rights with J&J for abiraterone in Japan

10/11/2013 | Reuters

AstraZeneca and Johnson & Johnson agreed to jointly promote the latter's prostate cancer drug abiraterone in Japan. The drug, marketed as Zytiga in the U.S. and Europe, is under regulatory review in Japan.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA
Assistant General Counsel, Regulatorya
Cardinal Health
Waukegan, IL
Chief Operating Officer
Health Plan of San Joaquin
French Camp , CA